Kodiak Sciences Inc.
KOD
Peringkat dalam Saham
#3122
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Harga Saham
$93.93
Kapitalisasi Pasar
$5.90B
Perubahan (1 hari)
2.82%
Perubahan (1 tahun)
430.65%
Negara
US
Perdagangan Kodiak Sciences Inc. (KOD)
Kategori
Healthcare
Laba untuk Kodiak Sciences Inc. (KOD)
Laba pada Jun 2026 TTM: $-241.99M
Menurut laporan keuangan terbaru dari Kodiak Sciences Inc., laba saat ini perusahaan adalah $-241.99M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-260.49M, peningkatan dibandingkan laba tahun 2022 sebesar $-333.82M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Kodiak Sciences Inc. dari 2016 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-241.99M | 37.34% |
| 2024 | $-176.21M | -32.36% |
| 2023 | $-260.49M | -21.97% |
| 2022 | $-333.82M | 25.03% |
| 2021 | $-266.99M | 100.60% |
| 2020 | $-133.10M | 181.00% |
| 2019 | $-47.37M | 14.29% |
| 2018 | $-41.44M | 48.35% |
| 2017 | $-27.94M | 63.06% |
| 2016 | $-17.13M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -2,279.76% |
US
|
|
| $-3.09B | 1,175.65% |
US
|
|
| $-4.02B | 1,559.63% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -906.07% |
NL
|
